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The timing of debulking surgery in advanced ovarian cancer
(AOC) has been the focus of debate and controversy in the in-
ternational community for almost a decade.1-4 Although sup-
porters of primary debulking surgery (PDS) advocate signiﬁcantly
better overall survival (OS) and progression-free survival rates,
with even a signiﬁcantly favorable impact on the patterns of re-
lapse,4 opponents argue higher morbidity in a highly heteroge-
neous and often fatal disease.1-3 For more than two decades, we
have known that each 10% increase in maximal cytoreduction is
associated with a 5.5% increase in median survival, even after
controlling for all other known patient- and tumor-speciﬁc
variables.5,6 However, because of the unusual tumor biology
and clinical behavior of AOC, with a typical diffuse peritoneal
dissemination, in the majority of cases complete debulking is
associated with multivisceral resections that require extensive
surgical expertise, training, and infrastructural support to not
lead to an exponential increase in morbidity.7
Neoadjuvant chemotherapy (NAC) and interval debulking
surgery (IDS) have been considered as ways to reduce surgical
morbidity; however, the oncologic safety of these approaches has
never been proven in a maximal effort setting of high surgical
expertise.2,3 The inconsistent quality of the surgical trials that have
addressed this matter so far; the broad variation in practice na-
tionally and internationally; and the still unanswered questions of
fragility scores, biomarkers, and valid predictors of operability have
led to strong polarization and controversy worldwide, which gives
a clear signal of the need for further evidence.
As a network of European institutions dedicated to high-
quality gynecologic oncology care, we address some key points
about this highly controversial topic and express some serious
concerns related to a potential patient’s compromise through sub-
optimal therapeutic strategies. Our statement is timed to the recent
publication of the Society of Gynecologic Oncology and ASCO
statement about the use of NAC in AOC, which provides guidance
on the optimal timing of surgery and identiﬁes diagnostic tools
that facilitate the patient selection process.1
A multi-institutional study of 1,538 women with AOC treated
at six National Cancer Institute–designated cancer centers showed
that NAC is associated with shorter OS in stage IIIC disease
compared with PDS (median OS, 33 v 43 months; hazard ratio,
1.40; 95% CI, 1.11 to 1.77).8 Although the study was not ran-
domized, these ﬁndings add to the abundant clinical experience
that patients who undergo PDS appear to have a better outcome in
specialized, high-volume centers.6,9-12
The two main phase III trials that have led to the broad
implementation of NAC in AOC are the European Organisation for
Research and Treatment of Cancer (EORTC) Neoadjuvant Che-
motherapy or Primary Surgery in Stage IIIC or IV Cancer trial 2
and Primary Chemotherapy Versus Primary Surgery for Newly
Diagnosed Advanced Ovarian Cancer (CHORUS) trial.3 Both trials
have generated ﬁndings that demonstrate a noninferior oncologic
performance of NAC-IDS with lower surgical morbidity and
mortality scores. On this basis, the Society of Gynecologic On-
cology recommends that ﬁt patients with seemingly resectable
AOC receive either NAC-IDS or PDS as equivalent alternatives.1
How safe is it to extrapolate and project the ﬁndings of the EORTC
and CHORUS trials to all patients with AOC, even though the
patients and tumor proﬁle represented in both studies show a clear
selection bias as emphasized by the study authors.2,3 The low
recruitment rate in CHORUS, with an average of only 1.35 sur-
geries per year in centers that serve. 1 million patients, indicates
a signiﬁcant selection bias. A similar amount of selection bias is
assumed in the EORTC trial in which large centers participated but
recruited an average of 1.85 patients per year. In addition, the very-
low complete resection rates in both trials suggest that mainly
patients believed to be inoperable were recruited into both trials.
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The observation of poorer-than-expected patient characteristics
ﬁts well with the assumption that the tumor burden of the
recruited patients was rather high, with 61.6% of patients in the
EORTC trial having metastatic lesions . 10 cm.2 Furthermore,
20% of the patients in the CHORUS trial had a performance status
of $ 2.3 The generalization of results from such highly selected
adverse subgroups risks extrapolation to patients who are ﬁt and
present with potentially resectable disease. The extrapolation
equivalence of PDS and NAC-IDS in this patient cohort is not
justiﬁed and could lead to potentially curative treatment being
withheld from a signiﬁcant proportion of patients. We doubt that
any chemotherapy trial would have received such broad recog-
nition if only 20% of the standard chemotherapy dose were ap-
plied. Better survival rates after PDS in the subgroup of patients
with metastases , 5 cm support this statement.13
The fact that the impact of residual disease becomes diluted in
the NAC setting is a potential signal of chemotherapy-induced
altered tumor biology. Despite a signiﬁcant increase in complete
tumor resection rates with IDS, this has failed to be translated into
the expected equivalent increase in survival.2,3 This failure can only
be explained by the hypothesis that completely different mecha-
nisms apply in settings that have yet to be deﬁned and may have
to do with the effect of NAC selection, which may change the
characteristics of the tumor encountered at NAC-IDS.14 Further
trials that explore the mechanisms of platinum resistance induced
by modality of treatment and that deﬁne the role of tumor biology
in determining resectability and survival in relation to surgical
effort are warranted.
The iatrogenic impact on quality of life (QoL) is another
powerful tool of assessing treatment success. Physicians must share
data with their patients about comparative morbidity, survival, and
QoL in plain language to ensure that patients make more informed
decisions.1 Opponents of radical PDS often argue that long-term
impairment of postoperative QoL exists. In the EORTC and
CHORUS prospectively randomized studies, no signiﬁcant dif-
ferences in QoLwere identiﬁed between treatment arms; therefore,
one cannot presume a long-term impairment in QoL derived from
the higher radicality associated with PDS.2,3,15,16 Approximately
10% of patients did not undergo surgery in the neoadjuvant arms
of either trial because of death, complications, or tumor pro-
gression before the scheduled IDS. Thus, only the ﬁttest and most
favorable patients were included in the postoperative adverse event
analysis and interviewed about their postoperative QoL. This se-
rious bias led to the decision to omit all statistical values for
treatment burden analyses that presumably compared PDS and
IDS in the EORTC trial publication.2
With all these challenges, patient selection is key to successful
outcomes if we are careful not to expose patients unﬁt for surgery
to radical cytoreduction and, on the other hand, not to withhold
potential life-extending treatment from patients who would
beneﬁt. Even patients with stage IV disease have a signiﬁcant
survival beneﬁt if operated tumor free compared with patients
with unresectable disease for whom NAC or even primary che-
motherapy should be considered.17 Preoperative examinations,
such as with computed tomography (CT) imaging and CA-125
testing, have been described as valuable assessments of the extent
of disease and the feasibility of surgical resection.1 Although
a preoperative CT scan might detect inoperable metastases, it
appears to have a low sensitivity for accurately describing tumor
lesions at key sites.18 Numerous studies have shown that the
prediction of suboptimal cytoreduction through CT imaging
has signiﬁcant limitations and cannot be cross validated.
Therefore, CT imaging should not be used as a single tool to
guide patient management.19-24 The same applies to testing CA-
125 levels, a speciﬁc cutoff of which has never been validated as
a predictor of operability. We suggest that the limitations of all
currently available tests to predict inoperability and overall
surgical outcome be considered further. This area of research is
ongoing, and until we have better tools, the clinical imple-
mentation of such methods should be done with caution be-
cause of their unproven reliability and risk to patients with
resectable disease who might be denied surgery on the basis of
unvalidated tools alone.
Diagnostic laparoscopy in a context of preoperative assess-
ment has also been described as feasible and provides a reliable
evaluation of the extent of disease burden.1 Laparoscopies may
provide histologic tissue diagnosis and thus identify patients with
low-grade histology who would not beneﬁt from NAC for non-
ovarian neoplasms. However, their value in improving survival in
unselected patient cohorts has never been shown. Laparoscopy can
differentiate and select patients with low versus high tumor burden
and result, as expected, in better survival and resectability ﬁgures
for those with low tumor burden.25 This knowledge, though, does
not help with the challenge of adequately treating patients with
high tumor load who often are excluded from surgery by these
laparoscopic series, which again leads to highly selected favorable
results from patients with low tumor burden.26 So far, most series
that used laparoscopy for selection have reported a higher rate of
unsuccessful surgeries with residuals . 1 cm than in unselected
series of consecutive patients with upfront debulking in expert
centers.11,27,28 Novel strategies relying on predictive and prognostic
biomarkers with innovative bioengineering tools, and radiomics
classiﬁcation features to deﬁne tumour dissemination patterns and
biology in AOC may change the face of patient management and
help to develop algorithms that will prospectively estimate the
relative operative morbidity and beneﬁt associated with PCS versus
NAC and will objectify measuring residual disease.29
Surgical outcome is affected not only by tumor biology and
patient-related factors that cannot be inﬂuenced, but also by surgical
and infrastructural expertise. The European Society of Gynecologic
Oncology recently published criteria for the quality of AOC
surgery and recommended PDS in patients expected to undergo
upfront debulking to no residual tumor with a reasonable (ex-
pected) complication rate.30,31 Caution should be heeded to not
recruit NAC-IDS cases to ﬁll the gaps that arise from suboptimal
expertise and inadequate infrastructural setting.
We believe that surgical questions can only be answered
sufﬁciently in studies with adequate surgical quality. This unmet
need has resulted in the drive to design and now commence
a further randomized trial to evaluate the optimal time point of
surgery.
The Trial on Radical Upfront Surgery in Advanced Ovar-
ian Cancer (TRUST), an initiative of the Arbeitsgemeinschaft
Gynaekologische Onkologie study group together with the North-
Eastern German Society of Gynaecologic Oncology, and in-
ternational collaborators, has been designed to meet these criteria
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and has started recruitment. Participating centers went through
a rigorous quality assessment protocol to conﬁrm surgical and
infrastructural quality. Quality assurance criteria for center eligi-
bility include $ 36 radical PDSs per year for stage IIIC and IV
disease that achieve complete tumor clearance in $ 50% of cases.
The criteria also include availability of the necessary infrastructure,
such as an interdisciplinary setting, intensive care, and blood
products. All centers were visited and audited at initiation, and
regular central monitoring is performed. Furthermore, partici-
pating surgeons had to state their commitment to include and
randomly assign all eligible patients to eliminate possible selection
bias, such as referral of mainly ﬁt patients in high-volume centers,
and to record all patients with presumed AOC in a central registry.
The complete abolishment of all possible clinical trial–related
selection bias is impossible, but we have prospectively attempted to
ameliorate and moderate these biases within TRUST through
robust mechanisms of recruitment and documentation to better
reﬂect clinical reality. Moreover, by accepting that high-volume
centers may reﬂect a selection bias of patients who are able to reach
these centers (ie, healthier, wealthier patients), we also equally
accept that these centers function as tertiary referral destinations
for cases deemed inoperable or more challenging for treatment in
smaller centers. This means that patient cohorts in larger-volume
centers often represent a collective of rather challenging, rare, and
difﬁcult cases that, again, may inﬂuence survival.
TRUST hopefully will not only further enlighten the adequate
management of patients with AOC but also establish through the
formation of a large translational platform predictive and prog-
nostic biomarkers of operability and survival and identify valid
fragility scores for the vulnerable population toward a more in-
dividualized surgical approach of this challenging disease.
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